New York, NY (January 15, 2025) – Parambil, an AI-driven legal tech company, has announced a $2M pre-seed funding round led by Daybreak Ventures. The funding will accelerate the company’s mission to transform complex litigation through high-quality, AI powered medical record analysis. Parambil's products have already demonstrated higher accuracy than human reviewers and the company is supporting cases ranging from single event occurrences to some of the most notable and complex mass tort cases in the country.

2024 was a pivotal year for Parambil, marked by the expansion of its platform to support over 50 fully-onboarded legal clients — up from three in its founding year — as well as more in its first-of-its-kind MDL pilot program. This rapid growth reflects the demand for AI-driven solutions that dramatically enhance efficiency without compromising accuracy.

“Our goal is to provide the legal industry with high-quality facts that enable more effective and efficient litigation,” said Sara Dwyer, Founder & CEO of Parambil. “We’re building the foundation for a future where AI not only improves outcomes but also transforms how firms manage data in complex cases.”

Transforming Litigation with Reliable AI

Parambil’s products have already proven to outperform human reviewers, delivering 44% more correct information and 70% fewer inaccuracies. These results translate into stronger plaintiff representation, better defense strategies, and faster and cheaper resolution for all parties involved. The company’s work spans mass torts, medical malpractice, catastrophic personal injury cases, and environmental exposure claims.

‍
In 2024, Parambil achieved a key milestone by partnering with the leadership team of one of the largest and most complex mass torts cases in the U.S. Described by case leaders as “the most intricate litigation” they’ve encountered, this opportunity underscores the scalability and sophistication of Parambil’s platform. The company’s tools are now being piloted by dozens of national and regional participating law firms as part of the ongoing litigation in addition to its dedicated client roster.

‍

Prominent attorney Jay Edelson notes, "the big question has always been: When will generative AI truly work for the mass tort bar? That moment appears to be now."

‍

New Product Innovations

Parambil continues to expand its suite of offerings to meet the diverse needs of law firms, insurance companies, and in-house teams:

• Proof: The flagship product for mass torts, enabling large-scale medical record analysis, claims validation, and evidence preparation.
• MedView: offering on-demand summaries and queries for medical and billing records, critical for personal injury and bellwether cases.
• Insights Suite: helping firms identify potential mass torts cases, uncover causal links, and synthesize data to support case strategies and best identify bellwether cases.

These tools are designed to address the increasing complexity of litigation and enable law firms to manage large data sets more effectively.

‍

Strategic Partnerships and Market Impact

Parambil has also formed strategic partnerships to bolster its capabilities:

• National Records Retrieval (NRR): Integrating with a leading record retrieval company to streamline data ingestion for law firms.
• Medical Review Partnership: Collaborating with a private-equity-backed service provider with over 400 medical professionals to enhance quality control and offer optional human review services.

These partnerships ensure that Parambil’s platform delivers unparalleled accuracy, efficiency, and scalability.

‍

A Strong Team

Parambil is led by Founder & CEO Sara Dwyer, who brings expertise in life sciences and AI from her time at McKinsey and holds a degree in Computer Science from the University ofPennsylvania. Sara started the company with Dr. Ralph Horwitz, Parambil’s Chief Medical Officer, a distinguished physician, professor, and former Head of Medicine at Yale andStanford. Ralph’s extensive experience includes serving as Dean of Case Western ReserveUniversity School of Medicine, a Senior VP at GSK, and as an expert witness in high-profile litigation. The team is also advised by Dr. Chris Callison-Burch, a prominent AI researcher and Sara’s former professor at Penn.

‍

About Parambil

Parambil is an AI-powered legal tech company focused on delivering high-quality medical record analysis and litigation support for law firms, insurance companies and in-house teams involved in mass torts, personal injury, and catastrophic cases. Parambil’s innovative products, including Proof, MedView, and Insights, provide transformative solutions for the evolving legal landscape. To learn more about us go to Parambil.com.